Design and validation of new genotypic tools for easy and reliable estimation of HIV tropism before using CCR5 antagonists

Journal of Antimicrobial Chemotherapy

Volumn 63, Issue 5, 2009, Pages 1006-1010

  Poveda, Eva ^a   Seclén, Eduardo ^a   González, María Del Mar ^a   García, Federico ^b   Chueca, Natalia ^b   Aguilera, Antonio ^c   Rodríguez, Jose Javier ^c   González Lahoz, Juan ^a   Soriano, Vincent ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^c HOSPITAL DE CONXO   (Spain)

Author keywords

Genotypic algorithm; Maraviroc; PSSM; Trofile; Tropism

Indexed keywords

CHEMOKINE RECEPTOR CCR5 ANTAGONIST; MARAVIROC;

ANALYTIC METHOD; ARTICLE; CLINICAL ASSESSMENT TOOL; CLINICAL TRIAL; GENETIC ALGORITHM; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PREVALENCE; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SPAIN; VALIDATION PROCESS; VIRAL GENETICS; VIRUS CELL INTERACTION; VIRUS DETECTION;

ALGORITHMS; GENOTYPE; HIV; HIV INFECTIONS; HUMANS; RECEPTORS, HIV; SENSITIVITY AND SPECIFICITY; SPAIN; VIROLOGY;

EID: 64649102626     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp063     Document Type: Article

References (30)

1. Anon. FDA approves maraviroc tablets. AIDS Patient Care STDs 2007; 21: 702.
2. Roberston D. US FDA approves new class of HIV therapeutics. Nat Biotechnol 2003; 21: 470-1.
3. Briz V, Poveda E, Soriano V. HIV entry inhibitors: Mechanisms of action and resistance pathways. J Antimicrob Chemother 2006; 57: 619-27.
4. Berger E, Doms R, Fenyö E et al. A new classification for HIV-1. Nature 1998; 391: 240.
5. Esté J, Telenti A. HIV entry inhibitors. Lancet 2007; 370 81-8.
6. Dorr P, Westby M, Dobbs S et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-HIV type 1 activity. Antimicrob Agents Chemother 2005; 49: 4721-32.
7. Castonguay L, Weng Y, Adolfsen W et al. Binding of 2-aryl-4(piperidin-1yl)butanmines and 1,3,4-trisubstitued pyrrolidines to human CCR5: A molecular modeling-guided mutagenesis study of the binding pocket. Biochemistry 2003; 42: 1544-50.
8. Gulick R, Lalezari J, Goodrich J et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008; 359: 1429-41.
9. Fatkenheuer G, Nelson M, Lazzarin A et al. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med 2008; 359: 1442-55.
10. Poveda E, Briz V, Quinones-Mateu M et al. HIV tropism: Diagnostic tools and implications for disease progression and treatment with entry inhibitors. AIDS 2006; 20: 1359-67.
11. Whitcomb J, Huang W, Fransen S et al. Development and characterization of a novel single-cycle recombinant-virus assay to determine HIV type 1 coreceptor tropism. Antimicrob Agents Chemother 2007; 51: 566-75.
12. Chan S, Speck R, Power C et al. V3 recombinants indicate a central role for CCR5 as coreceptor in tissue infection by HIV type 1. J Virol 1999; 73: 2350-8.
13. Jensen M, Van't Wout A. Predicting HIV-1 coreceptor usage with sequence analysis. AIDS Rev 2003; 19: 145-9.
14. Low A, Dong W, Chan D et al. Current V3 genotyping algorithms are inadequate for predicting X4 co-receptor usage in clinical isolates. AIDS 2007; 21: F17-24.
15. Poveda E, Briz V, Roulet V et al. Correlation between a phenotypic assay and three bioinformatics tools for determining HIV coreceptor use. AIDS 2007; 21: 1487-90.
16. Raymond S, Delobel P, Mavigner M et al. Correlation between genotypic predictions based on V3 sequences and phenotypic determination of HIV-1 tropism. AIDS 2008; 22: F11-7.
17. Garrido C, Roulet V, Chueca N et al. Evaluation of eight different bioinformatics tools to predict viral tropism in different HIV-1 subtypes. J Clin Microbiol 2008; 61: 694-8.
18. de Mendoza C, Van Baelen K, Poveda E et al. Performance of a population-based HIV-1 tropism phenotypic assay and correlation with V3 genotypic prediction tools in recent HIV-1 seroconverters. J Acquir Immune Defic Syndr 2008; 48: 241-4.
19. Pillai S, Good B, Richman D et al. A new perspective on V3 phenotype prediction. AIDS Res Hum Retroviruses 2003; 19: 145-9.
20. Jensen M, Li F, van't Wont A et al. Improved co-receptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of HIV type 1 env V3 loop sequences. J Virol 2003; 77: 13376-88.
21. Sing T, Beerenwinked N, Lengaver T. Learning mixtures of localized rules by maximizing the area under the ROC curve. In: Proceedings of the First International Workshop on ROC Analysis in Artificial Intelligence, Valencia, Spain, 2004. pp. 89-96. Association for Computing Machinery, New York, NY, USA.
22. De Jong J, De Ronde A, Keulen W et al. Minimal requirements for the HIV type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution. J Virol 1992; 76 3852-64.
23. Cardozo T, Kimura T, Philpott S et al. Structural basis for coreceptor selectivity by the HIV type 1 V3 loop. AIDS Res Hum Retroviruses 2007; 23: 415-26.
24. Fouchier R, Groenink M, Kootstra N et al. Phenotype-associated sequence variation in the third variable domain of the HIV type 1 gp120 molecule. J Virol 1992; 66: 3183-7.
25. Recordon-Pinson P, Soulié C, Anies G et al. Evaluation of the genotypic prediction of HIV-1 coreceptor tropism in a clinical setting. Antivir Ther 2008; 13 Suppl 3: A113.
26. Obermeier M, Sichtig N, Braun P et al. Determination of HIV-1 coreceptor usage in German patients - comparison of genotypic methods with the Trofile phenotypic assays. Antivir Ther 2008; 13 Suppl 3: A112.
27. Soulié C, Derache A, Aimé C et al. Comparison of two genotypic algorithms to determine HIV-1 tropism. HIV Med 2008; 9: 1-5.
28. Trinh L, Han D, Huang W et al. Technical validation of an enhanced sensitivity Trofile HIV coreceptor tropism assay for selecting patients for therapy with entry inhibitors targeting CCR5. Antivir Ther 2008; 13 Suppl 3: A128.
29. Chueca N, Martin L, Alvarez M et al. A combination of bioinformatics tools can be accurately used for the screening of coreceptor usage in clinical samples. Antivir Ther 2008; 13 Suppl 3: A106.
30. Poveda E, Seclén E, Gonzalez M et al. Improvement of genotypic algorithms to predict HIV-1 tropism in treatment-experienced patients: correlation with Trofile results. Antivir Ther 2008; 13 Suppl 3: A109.